All News

RheumNow Podcast square

RheumNow Podcast – Ro, Ro, Ro52 (9.12.2025)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. Are there benefits to diet or vegan diets? What's the effect of menopause on CTD?  Ro52 makes a big entrance with all our ILD coverage this month.

Read Article
MTX.box

SMART study - Single vs. Split Dose Methotrexate in RA

Jack Cush, MD

Split dose weekly, oral methotrexate (MTX) was shown to be superior to single dose MTX in treating active rheumatoid arthritis (RA) patients.

Read Article
checklist on clipboard

How to assess ILD in your patients?

Janet Pope, MD, MPH, FRCPC

Have a high index of suspicion in your patients with connective tissue disease (especially systemic sclerosis, inflammatory myositis), and rheumatoid arthritis.

Read Article
APLAR GRAY

SLE and Osteoporosis

Sheila Reyes, MD

In one of the SLE sessions at the APLAR 2025 Congress, Prof. Sandra Navarra discussed the assessment and management of osteoporosis in SLE patients, particularly glucocorticoid-induced osteoporosis (GIOP) and this article reviews the highlights and key takeaways from her talk.

Read Article
APLAR on red background

PAH diagnosis and management in the context of CTD ILD

Aurelie Najm, MD, PhD

Pulmonary arterial hypertension (PAH) is a serious complication of connective tissue disorders. Approximately 25% of patients with PAH have an underlying CTD, making CTD-PAH the second most common cause of PAH. During the session on Management of Lung Complications in CTD at APLAR 2025, Prof. Dinesh Khanna and Masataka Kuwana provided an excellent overview of PAH diagnosis and management strategies the context of CTD-ILD.

Read Article
guidelines.recommendations.jpg

ERS/EULAR guidelines for CTD-related interstitial lung disease

Jack Cush, MD

The European Respiratory Society (ERS) and European Alliance of Associations for Rheumatology (EULAR) have published clinical practice guidelines for the evaluation and management of connective tissue diseases (CTD) associated interstitial lung disease (ILD) in two simultaneous publications in the European Respiratory Journal and Annals of Rheumatic Diseases.

Read Article
Is it #lupus? Interesting study by @escheriKYA et al. showing comparable diagnostic performance of SLERPI (93%) in 🇵🇭 patients vs. SLICC and EULAR/ACR criteria A practical alternative tool that can be used by clinicians in a resource-limited setting 🤔 @RheumNow #APLAR25 https://t.co/xByBkjEr3r

Links:

sheila RHEUMarampa ( View Tweet)
Regional Disparities in DMARD Management for RA Treatment Dr. Aurelie Najm, Glasgow, reports on a session on "Updates on DMARDs treatment: global standards and regional adaptations" from the APLAR 2025 Congress in Fukuoka, Japan. https://t.co/zDo5NxKtbE https://t.co/kF9FxyWkIQ

Links:

Dr. John Cush RheumNow ( View Tweet)
ERS/EULAR guidelines for CTD-related interstitial lung disease The European Respiratory Society (ERS) and European Alliance of Associations for Rheumatology (EULAR) have released clinical practice guidelines for evaluating and managing connective tissue diseases (CTD) https://t.co/2mmxsor4ND
Dr. John Cush RheumNow ( View Tweet)
This slide reflects the rheumatologist’s goals for treating #lupus Prof. Mosca also highlights the fact that achieving targets is as important as maintaining these treatment targets. @RheumNow #APLAR25 https://t.co/u8fw3fThXI

Links:

sheila RHEUMarampa ( View Tweet)
Prof. Eric Morand on the SLE T2T approach. Ultimate goal is remission but we know that not all patients achieve this state. Thru the T2T approach, low dse activity (LLDAS) is an acceptable target & a protective alternative goal @RheumNow #APLAR25 #Lupus https://t.co/vz7E5prps0

Links:

sheila RHEUMarampa ( View Tweet)
Gout: Highlights from APLAR 2025 Dr. Sheila Reyes, The Philippines, reports on highlights and takeaways from lectures on the treatment of gout from the APLAR 2025 Congress in Fukuoka, Japan. https://t.co/Fxd3MBUYrT https://t.co/gKjHlJXttT

Links:

Dr. John Cush RheumNow ( View Tweet)
Stay sharp in RA, PsA & SpA care. Get the latest breakthroughs + expert insights at RWCS 2026. Don’t miss 'Year in Review: Rheumatology Advances.' Register now: https://t.co/majEsY4tXK https://t.co/fgGniR1OGk

Links:

RWCS RWCSmtg ( View Tweet)
Where are we now—and where are we going in ILD treatment? 📅 September 9 (TONIGHT!)| ⏰ 7PM EST (LIVE) Rheumatology leaders Drs. Sindhu Johnson, Dr. Anna-Maria Hoffmann-Vold, Dr. Scott Matson, and Dr. Jack Cush will review the latest ACR & EULAR guidelines on interstitial lung https://t.co/E30AirP5WX
Dr. John Cush RheumNow ( View Tweet)
September to Remember (9.5.2025) Dr. Jack Cush reviews the news and journal reports from RheumNow. This week - unemployment, diagnosing Sjogren's and a lot of ILD. https://t.co/dPdweMaJuN https://t.co/aExU5kV26Q

Links:

Dr. John Cush RheumNow ( View Tweet)
Based on a survey in Japan, resolution of dry mouth was the most important symptom resolution reported by SJD pts. The JCR CPG for SjD suggests RTX for glandular involvement while BEL for extra-glandular involvements. #APLAR25 @RheumNow https://t.co/SsUvQIM9Eu

Links:

sheila RHEUMarampa ( View Tweet)
Is it D2T RA or Clinical inertia? Concept introduced by Dr Kaneko, Japanese Keio RA cohort, followed for 5yrs 5% patients not fitting the D2T RA definition have MDA or HDA The drivers of persistent DA in RA: -overestimation of treatment effectiveness -avoidance of treatment https://t.co/0pkDaUFH4R

Links:

Aurelie Najm AurelieRheumo ( View Tweet)
Interesting data shared by Dr. Sandhya Pulukool on Asian pts with SjD vs. Caucasians: - Younger age of onset except in Japan - Higher female to male ratio @RheumNow #APLAR25 https://t.co/RPM9zI4tVQ

Links:

sheila RHEUMarampa ( View Tweet)
Prof Takeuchi on DMARDs treatment and regional disparities For similar dose, serum concentration of the polyglutamate (active) form of MTX is much higher in Japanese than US patients And also high levels achieved much quicker in Japanese than US patients This is strong https://t.co/ikp63wWifj

Links:

Aurelie Najm AurelieRheumo ( View Tweet)
What’s new in RA Pathogenesis in #APLAR25 by Ellen Gravellese Take home message: there is still hope for synovial biopsies to be a biomarker for prediction of response to treatment As a synovial biopsy expert, I am not convinced of this one, but time will tell @APLAR_org https://t.co/EEw5ncKa1r

Links:

Aurelie Najm AurelieRheumo ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×